GlassScriptPhysician profile
Frosty Dr Moore
NPI 1073517736
$16,518.74
in general payments reported to CMS, 2019-2025
32 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,556 · 2020: $480 · 2021: $5,092 · 2022: $2,045 · 2023: $1,481 · 2024: $1,992 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,446 · Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,445.62 |
| Food and Beverage | $900.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $11,096.21 | 2019-2025 | Procare |
| Acelrx Pharmaceuticals, INC. | $2,196.53 | 2021 | |
| Smith+Nephew, INC. | $476.00 | 2019-2023 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Radius Health, INC. | $430.76 | 2019-2025 | Tymlos |
| Orthalign INC | $409.11 | 2019-2024 | Orthalign Plus |
| Zimmer Biomet Holdings, INC. | $300.45 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $190.33 | 2020-2025 | Exparel, Iovera |
| Si-Bone, INC. | $158.65 | 2022 | |
| Anika Therapeutics, INC. | $156.15 | 2021-2025 | Tactoset, Integrity Implant |
| Depuy Synthes Sales INC. | $114.79 | 2021-2024 | Truespan Orthocord, Monovisc, Orthovisc |
| Catalyst Orthoscience | $110.31 | 2022 | |
| Abbott Laboratories | $102.60 | 2019-2025 | Proclaim |
| Ferring Pharmaceuticals INC. | $98.84 | 2019-2025 | Euflexxa |
| Osteocentric Technologies, INC. | $94.63 | 2019 | |
| Stryker Corporation | $76.76 | 2021-2024 | 1788 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $65.34 | 2019-2024 | Physio-Stim |
| Zyla Life Sciences, INC. | $61.28 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $56.11 | 2025 | |
| Kerecis Limited | $48.61 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medacta USA, INC. | $37.48 | 2021-2022 | |
| Orthogenrx INC. | $36.81 | 2019 | |
| Mimedx Group, INC. | $33.10 | 2025 | |
| Boston Scientific Corporation | $25.56 | 2021 | |
| Ermi LLC | $23.51 | 2023 | |
| Fidia Pharma USA INC. | $23.35 | 2025 | Triluron, Hymovis |
| Pfizer INC. | $16.95 | 2020 | |
| Paragon 28, INC. | $16.84 | 2019 | |
| Bioventus LLC | $14.71 | 2020 | |
| Terumo Bct, INC. | $12.61 | 2019 | |
| Pacira Therapeutics, INC. | $11.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.95 | 2020 | |
| Spinesmith Holdings, LLC | $10.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frosty Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.